Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.68 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.68 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.43 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62557 | 0.82 | GABRA1 (1.00) | GABRA1GABRB2MAPT | |
| SCHEMBL5925081 | 0.82 | PTGS2 (0.54) | GABRA1GABRB2AKR1B1TDP1PTGS2 | |
| SCHEMBL27465524 | 0.82 | AKR1B1 (0.48) | GABRA1GABRB2AKR1B1TDP1PTGS2 | |
| SCHEMBL29933724 | 0.82 | PTGS2 (0.54) | GABRA1GABRB2AKR1B1TDP1PTGS2 | |
| SCHEMBL2875381 | 0.82 | AKR1B1 (0.52) | GABRA1GABRB2AKR1B1TDP1PTGS2 | |
| SCHEMBL9498776 | 0.81 | GABRA1 (0.63) | GABRA1GABRB2 | |
| SCHEMBL14530966 | 0.80 | AKR1B1 (0.67) | GABRA1GABRB2AKR1B1TDP1PTGS2 | |
| SCHEMBL6243179 | 0.79 | AKR1B1 (0.46) | GABRA1GABRB2AKR1B1TDP1PTGS2 | |
| SCHEMBL509855 | 0.79 | AKR1B1 (0.64) | GABRA1GABRB2AKR1B1TDP1PTGS2 | |
| SCHEMBL30688321 | 0.79 | AKR1B1 (0.64) | GABRA1GABRB2AKR1B1TDP1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116730918-A | Aporphine derivative, and preparation method and application thereof | 苏州大学 | 2023-09-12 | — | — | CN | disclosed |
| EP-3230226-A2 | SYNTHETIC WATER RETENTION AGENT AND RHEOLOGY MODIFIER FOR USE IN CEMENT, ADMIXTURES | Rohm and Haas Company (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170240476-A1 | SYNTHETIC WATER RETENTION AGENT AND RHEOLOGY MODIFIER FOR USE IN CEMENT ADMIXTURES | ROHM & HAAS (US) | 2017-08-24 | — | — | US | disclosed |
| US-8067598-B2 | Heterofused piperidines as orexin antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | disclosed |
| EP-2144906-B1 | HETEROCYCLES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-15 | — | — | EP | disclosed |
| EP-2144906-A1 | HETEROCYCLES AS OREXIN ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008122513-A1 | HETEROCYCLES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-16 | — | — | WO | disclosed |
| US-20080249125-A1 | HETEROCYCLIC DERIVATIVES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-10-09 | — | — | US | disclosed |
| EP-1546130-A1 | NOVEL PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASE STATES | AstraZeneca AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004029041-A1 | NOVEL PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASE STATES | ASTRAZENECA AB (SE) | 2004-04-08 | — | — | WO | disclosed |
| US-4672138-A | INTERMEDIATES FOR BENZO (B) THIOPHENES; HYPOTENSIVE AGENTS, DIURETICS | HOECHST ROUSSEL PHARMACEUTICALS INC. (US) | 1987-06-09 | — | — | US | disclosed |
| EP-0050326-B1 | BENZO(B)THIOPHENES | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1986-01-29 | — | — | EP | disclosed |
| EP-0155981-A2 | Derivatives of alkoxythiophenol; alkoxyphenolthio carbamates | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1985-10-02 | — | — | EP | disclosed |
| US-4537976-A | Benzo[b]thiophenes | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1985-08-27 | — | — | US | disclosed |
| US-4528399-A | Benzo[b]thiophenes intermediates | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1985-07-09 | — | — | US | disclosed |
| EP-0050326-A2 | Benzo(b)thiophenes | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1982-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249125-A1 | HETEROCYCLIC DERIVATIVES AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, HRH3 | GABRA1 149/4885GABRB2 146/4885AKR1B1 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.